about
Roles of lipoprotein receptors in the entry of hepatitis C virusConditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease ActivityTargeting viral infection by microRNA inhibitionZebrafish as a potential model organism for drug test against hepatitis C virusDisturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection.Dendritic cell-mediated, DNA-based vaccination against hepatitis C induces the multi-epitope-specific response of humanized, HLA transgenic mice.Screening compounds against HCV based on MAVS/IFN-β pathway in a replicon modelHepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cellsTargeting microRNA-122 to Treat Hepatitis C Virus Infection.Ineffective CD8(+) T-cell immunity to adeno-associated virus can result in prolonged liver injury and fibrogenesis.Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct.Long-Term Persistent GBV-B Infection and Development of a Chronic and Progressive Hepatitis C-Like Disease in Marmosets.Hepatitis C Virus Sensing by Human Trophoblasts Induces Innate Immune Responses and Recruitment of Maternal NK Cells: Potential Implications for Limiting Vertical Transmission.Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replicationPharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.Sofosbuvir and ABT-450: terminator of hepatitis C virus?Embryonic and induced pluripotent stem cells as a model for liver disease.Natural killer cells: multifaceted players with key roles in hepatitis C immunity.Cytokeratin 8 is increased in hepatitis C virus cells and its ectopic expression induces apoptosis of SMMC7721 cellsLy6C(hi) monocytes regulate T cell responses in viral hepatitis.HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.Hepatitis C viral protein translation: mechanisms and implications in developing antivirals.Telaprevir/boceprevir era: from bench to bed and back.The functional RNA domain 5BSL3.2 within the NS5B coding sequence influences hepatitis C virus IRES-mediated translation.Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells.Comparative analysis of NK-cell receptor expression and function across primate species: Perspective on antiviral defenses.Canine hepacivirus and idiopathic hepatitis in dogs from a Dutch cohort.Development of persistent HCV genotype 3a infection cell culture model in huh-7 cell.Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans.Hepatitis C virus targets the interferon-α JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes.Long-term propagation of serum hepatitis C virus (HCV) with production of enveloped HCV particles in human HepaRG hepatocytes.Virus-drug interactions--molecular insight into immunosuppression and HCV.
P2860
Q26777338-6703B9C5-EE12-43ED-9724-A0F9B5B78412Q27318504-1C8A979E-2D9F-4703-97B7-FACFDB1A718EQ27491314-0498324C-D00E-491A-A5C4-C31F919AC855Q28476465-D3EAF5E2-147B-48C3-9791-F84E59961EB5Q33837562-F8805497-FAC3-4445-B609-B8A8B5915351Q34028154-7C447FAD-76DF-4C41-92A3-6645F88C1D26Q34354669-B3BD7BC3-65DA-45D7-9C62-F20D650A8751Q34699732-8F9600FE-1842-44D8-94EB-3F4596CD7114Q35261089-AFEE4FA9-CEC4-43E7-B5E1-785D1B8DEB04Q35475399-41441E2F-5350-445F-8058-85C4B62E2ACDQ35489009-29EC854C-6A03-4DE5-9CE0-96F0789A443DQ35701365-E94A00B4-6953-438A-B75B-808656A8DA07Q36119372-57075F8F-BF72-4A6C-B77F-2D8317285E53Q36612971-5C89AD9B-9CDB-491A-A0EF-DEA4AE092A5DQ36667165-C81DD7C0-796B-4D13-8D3F-7E45497ACF8BQ36897890-E9378A8B-CD5B-4D2C-AC7D-F1C2E9F15AF8Q36980068-D34E33F9-FEEF-4247-9BFF-4A2E57DF1C0AQ37151472-864FC61D-2667-4986-995E-72FF8FDB30F5Q37208105-C0EFF5CB-9B1C-4F35-996B-2AD69E7E9426Q37351573-B3E24BA1-6699-43D6-973D-7D28F1F1F3C4Q37471718-D0806E6F-40C9-4C0F-B43A-237DDF025871Q37899939-17A34D49-75C3-452D-9366-079D173207FBQ38062524-AF7B60AB-F731-4161-A94D-B4BC08953900Q39539402-49166A88-C59C-45C2-BBE3-AA9613ADD2F3Q41384817-2B376C4F-D7C1-48C1-8D04-CC2D554D6EBCQ41993469-A9E7E8FD-8873-46F8-A04B-00D74D6D3F8AQ42214162-A0912903-1008-4711-B07C-20A1119C1E24Q42609571-02448BEF-1125-4CB8-ADC8-D52775A434A0Q42734199-65911A71-3504-49A5-8A87-579125CD232AQ42991206-255004EE-4121-4275-BFC7-D2B30C37ECCCQ43036339-2C519F54-AB95-4D39-8A49-E71E102E7DD7Q45358300-ACC9834E-C631-4A77-80CE-6B7ED18AE076
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Experimental models for hepatitis C viral infection.
@ast
Experimental models for hepatitis C viral infection.
@en
Experimental models for hepatitis C viral infection.
@nl
type
label
Experimental models for hepatitis C viral infection.
@ast
Experimental models for hepatitis C viral infection.
@en
Experimental models for hepatitis C viral infection.
@nl
prefLabel
Experimental models for hepatitis C viral infection.
@ast
Experimental models for hepatitis C viral infection.
@en
Experimental models for hepatitis C viral infection.
@nl
P2093
P2860
P356
P1433
P1476
Experimental models for hepatitis C viral infection.
@en
P2093
Andre Boonstra
Harry L A Janssen
Luc J W van der Laan
Thomas Vanwolleghem
P2860
P304
P356
10.1002/HEP.23138
P407
P577
2009-11-01T00:00:00Z